AdAlta granted Indian patent protecting AD-214

AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to announce that its first Indian patent relating to lead program, AD-214, has been granted by the Indian Patent Office.

Patent Number 398125, entitled "CXCR4 binding molecules", has an expiry date of 8 January 2036.

The new patent protects the i-body sequence used in AdAlta`s lead product, AD-214, sequences similar to this, and pharmaceutical compositions and derivatives containing these i-body sequences. The patent also protects the use of these sequences in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF), the lead indication for which AD-214 is being developed.

Patents are granted on a country-by-country basis, and India is the sixth country to grant patent protection under this application, following Australia (two patents), US (two patents), Japan, China and Singapore. Claims are being pursued in other major markets including the European Union.

AdAlta`s CEO and Managing Director, Dr Tim Oldham said:

"India is a significant pharmaceutical market in its own right, and is also a leading manufacturing location for biologic drugs and biosimilars (or generic biologies). This patent expands the protected market for AD-214 and provides additional security for AD-214`s global supply chain."